Table 1—

Patient characteristics at baseline

Patient no.	Sex	Aetiology of PH	Age yrs	P̄_pa mmHg	PVR WU	Cardiac index L·min⁻¹·m⁻²	Prior specific PH therapy	PVR response ≥20%
1^#	Female	CHD	62	42	5.6	2.4	None	Yes
2	Male	CTEPH	64	70	13.2	2	None	No
3^#	Male	iPAH	64	45	7.5	2.2	Ilo	No
4^#	Female	iPAH	62	63	17.2	1.9	Ilo	No
5^¶	Female	ILD	59	47	5.2	3.7	None	Yes
6^#	Male	iPAH	71	49	13.8	1.53	None	No
7	Female	iPAH	36	54	10.7	2.34	Ilo	No
8	Female	CTEPH	56	60	12.5	2.15	None	No
9^¶	Female	ILD	49	45	13.8	1.83	None	No
10^¶	Female	COPD	53	34	4.6	3.21	None	Yes
11^¶	Female	ILD	52	45	6.1	2.81	None	No
12^¶	Female	ILD	58	44	12.0	1.65	Ilo+Bos	No
13^¶	Female	COPD	63	27	3	2.34	None	No
14^#	Male	iPAH	71	47	9.8	2.05	None	No
15^#	Male	iPAH	43	35	5.6	3.03	CCB+Ilo	Yes
16	Female	CTEPH	59	28	4	3.01	None	No
17^¶	Female	COPD	80	34	5.8	2.49	None	Yes
18^#	Female	iPAH	38	70	16.4	1.95	CCB+Sil	No
19^#	Male	PAH	68	27	9.6	1.25	Sil	Yes
20^¶	Female	ILD	63	37	7.2	2.83	Bos	No

PH: pulmonary hypertension; P̄_pa: mean pulmonary arterial pressure; PVR: pulmonary vascular resistance; WU: Wood units; CHD: corrected congenital heart disease; CTEPH: nonoperable chronic thromboembolic PH; iPAH: idiopathic pulmonary arterial hypertension (PAH); ILD: chronic interstitial lung disease; COPD: chronic obstructive pulmonary disease; Ilo: iloprost aerosol; Bos: bosentan; CCB: high-dose calcium channel blockers; Sil: sildenafil. ^#: PAH patient; ^¶: patient with PH and chronic lung disease.